Emergent BioSolutions
EBS
C$9.01
Share price
3.45%
Change (1 day)
-6.73%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - Total debt
Total debt on the balance sheet as of March 2025 : C$0.90 Billion
According to Emergent BioSolutions 's latest financial reports the company's total debt is C$0.90 Billion. A company’s total debt is the sum of all current and non-current debts.
Emergent BioSolutions - Total debt on balance sheet (from 2004 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | C$0.95 B | -16.52% |
| 2023-12-31 | C$1.14 B | -40.19% |
| 2022-12-31 | C$1.90 B | 77.98% |
| 2021-12-31 | C$1.07 B | -3.91% |
| 2020-12-31 | C$1.11 B | 5.27% |
| 2019-12-31 | C$1.05 B | -2.11% |
| 2018-12-31 | C$1.08 B | 6277.26% |
| 2017-12-31 | C$16.97 M | -95.29% |
| 2016-12-31 | C$0.36 B | 5.19% |
| 2015-12-31 | C$0.34 B | 17.58% |
| 2014-12-31 | C$0.29 B | 341.34% |
| 2013-12-31 | C$65.99 M | 5.73% |
| 2012-12-31 | C$62.42 M | 3.22% |
| 2011-12-31 | C$60.47 M | 27.57% |
| 2010-12-31 | C$47.4 M | -31.44% |
| 2009-12-31 | C$69.14 M | -0.55% |
| 2008-12-31 | C$69.52 M | 20.3% |
| 2007-12-31 | C$57.79 M | 16.06% |
| 2006-12-31 | C$49.79 M | 259.13% |
| 2005-12-31 | C$13.86 M | -10.28% |
| 2004-12-31 | C$15.45 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Merck MRK | C$47.54 B | 5,134.19% | 🇺🇸 USA |
 SIGA Technologies SIGA | C$0.76 M | -99.92% | 🇺🇸 USA |
 GlaxoSmithKline GSK | C$32.49 B | 3,477.56% | 🇬🇧 UK |
 Celldex Therapeutics CLDX | C$4.67 M | -99.49% | 🇺🇸 USA |
 Pfizer PFE | C$83.63 B | 9,107.00% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | C$23.11 B | 2,444.54% | 🇮🇱 Israel |
 Soligenix SNGX | C$0.1 M | -99.99% | 🇺🇸 USA |